Last reviewed · How we verify
NCT07341399
Essential Amino Acid Supplementation in Adult Spinal Deformity Patients
NA trial testing Essential Amino Acid Supplement by Amino Co in Adult Spinal Deformity in 20 participants. Not yet recruiting.
1 March 2027
Quick facts
| Lead sponsor | University of Arkansas |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 20 |
| Start date | 1 May 2026 |
| Primary completion | 1 March 2027 |
| Estimated completion | 15 May 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Essential Amino Acid Supplement by Amino Co — full drug profile →
- Placebo
Conditions studied
- Adult Spinal Deformity — all drugs for Adult Spinal Deformity →
Sponsor
University of Arkansas
Who can join
Adults 40 to 65, any sex, with Adult Spinal Deformity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This will be a randomized double-blind placebo controlled clinical trial to determine if supplementing with essential amino acids (EAAs) for two weeks prior to, and 3 months after corrective spinal surgery in adults with spinal deformity can stimulate greater muscle protein turnover and whole-body protein balance, and enhance recovery after surgery when compared to a calorie matched placebo.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07341399
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Essential Amino Acid Supplement by Amino Co
Trials testing the same drug.
- NCT05935826 — Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) · Phase 3 · recruiting
Other recruiting trials for Adult Spinal Deformity
Currently open trials in the same condition.
- NCT07105189 — Feasibility of Wireless Continuous Vital Sign Monitoring and Impact on Patients Undergoing Adult Spinal Surgery in a Gen · NA · recruiting
- NCT04885244 — Prospective Evaluation of Complex Adult Spinal Deformity (CAD) Treated With Minimally Invasive Surgery · recruiting
- NCT04888104 — Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional · recruiting
- NCT04194138 — Complex Adult Deformity Surgery (CADS) · recruiting
Other University of Arkansas trials
Trials by the same sponsor.
- NCT07029776 — MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma · Phase 2 · not yet recruiting
- NCT07071766 — Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment · NA · recruiting
- NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
- NCT06604065 — Essential Amino Acids and Parkinsons Disease · Phase 1 · withdrawn
- NCT06565455 — Growing Healthy Children and Families in Rural Arkansas · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07341399 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Arkansas
- Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07341399.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing